
Vector-borne protozoan infections are responsible for a wide variety of illnesses (mainly malaria, trypanosomiasis and leishmaniasis) affecting tropical and subtropical areas, but increasingly diagnosed in nonendemic settings. This article summarizes the therapeutic developments for these conditions during the past decade and focuses specifically on treatment recommendations for returning travelers and migrants. The treatment of malaria has known the most spectacular improvements. Progress in the management of leishmaniasis and trypanosomiasis has also been substantial and includes introduction of new drugs into clinical practice, combinations of existing drugs, or new laboratory tools for treatment monitoring as well as extension of treatment indications to new groups of patients. Serious gaps still exist in terms of effectiveness and tolerance. Since the research pipeline is very limited for the coming 5-10 years, optimized combinations of existing drugs need to be urgently explored.
Trypanosoma brucei rhodesiense, Chagas disease, Plasmodium, Endemic Diseases, Epidemiology, Trypanosoma brucei gambiense, Recommendations, Mosquitoes, Prevalence, Leishmaniasis, Diagnostics, Visceral, Leishmania, Transients and Migrants, Travel, Drug combinations, Tsetse flies, Global, Disease burden, Protozoal diseases, Vectors, Management, Trypanosomiasis, American, Trypanosoma, Trypanosoma cruzi, Antiprotozoal Agents, 610, Drug development, Therapeutics, Travelers, Trypanosomiasis, Anopheles, Vector-borne diseases, Humans, Combination therapy, Protozoan Infections, Research, Developed Countries, African, Sleeping sickness, Malaria, Treatment, Clinical manifestations, Trypanosomiasis, African, Cutaneous, American, Travel Medicine, Leishmania donovani
Trypanosoma brucei rhodesiense, Chagas disease, Plasmodium, Endemic Diseases, Epidemiology, Trypanosoma brucei gambiense, Recommendations, Mosquitoes, Prevalence, Leishmaniasis, Diagnostics, Visceral, Leishmania, Transients and Migrants, Travel, Drug combinations, Tsetse flies, Global, Disease burden, Protozoal diseases, Vectors, Management, Trypanosomiasis, American, Trypanosoma, Trypanosoma cruzi, Antiprotozoal Agents, 610, Drug development, Therapeutics, Travelers, Trypanosomiasis, Anopheles, Vector-borne diseases, Humans, Combination therapy, Protozoan Infections, Research, Developed Countries, African, Sleeping sickness, Malaria, Treatment, Clinical manifestations, Trypanosomiasis, African, Cutaneous, American, Travel Medicine, Leishmania donovani
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 4 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
